What is it about?
A retrospective study of a GP database to determine if intermittent use of PDE5 inhibitors confers cardioprotectiion
Featured Image
Why is it important?
Patients (males in this study) with type II diabetes (T2DM) have a markedly increased risk of adverse cardiovascular events. In this study we found that intermittent use of PDE5 inhibitors as a management aid for erectile dysfunction leads to a marked cardioprotective effect. Patients taking PDE5 inhibitors had a reduction in all cause mortality, reduced incident myocardial infarction and reduced mortality following myocardial infarction
Perspectives
This study adds to a growing body of evidence that PDE5 inhibitors are cardioprotective and provides more evidence that the time is right to consider large randomised trials to confirm this positive benefit in patients at increased risk of heart disease
Professor Andrew Trafford
University of Manchester
Read the Original
This page is a summary of: Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all cause mortality, Artery Research, December 2014, Elsevier,
DOI: 10.1016/j.artres.2014.09.162.
You can read the full text:
Contributors
The following have contributed to this page
